Psoriasis is a common inflammatory skin condition involving 2–4% of the global population. It is clinically characterized by erythematous and scaly plaques that persist throughout life in variable severity and is in large part caused by T-lymphocyte dysfunction. Psoriasis is associated with an increased risk of developing co-conditions, such as obesity, hypertension, diabetes, lymphoma, stroke and psychological depraving traits like depression, anxiety and antisocial behavior - all resulting in a substantial impact on quality of life. Pathology onset is an interaction between genetic, environmental and immunological factors. Flares of Psoriasis can be triggered by local stimuli (eg. scratching), systemic factors such as infections or medication, or psychological factors like stress.

PDE4 inhibitor (UNI50001)

UNION is developing a new oral PDE4 inhibitor for psoriasis (UNI50001) and is currently preparing a Phase 2b study. Prior studies in patients with moderate to severe plaque psoriasis have shown UNI50001 to be efficacious in reducing disease severity.

About PDE4

PDE4 inhibition promotes intracellular accumulation of cyclic adenosine monophosphate (cAMP), suppressing the transcription of specific cytokines, such as TNF-α, Il-17 and IL-23, exerting anti-inflammatory effect reducing psoriasis scale formation and unwanted keratinocyte differentiation.

Back to Pipeline